The present invention is directed to a method for separating, characterizing and/or identifying microorganisms in a test sample. The method of the invention comprises an optional lysis step for lysing non-microorganism cells that may be present in a test sample, followed by a subsequent separation step. The method may be useful for the separation, characterization and/or identification of microorganisms from complex samples such as blood-containing culture media. The invention further provides for spectroscopic interrogation of the separated microorganism sample to produce measurements of the microorganism and characterizing and/or identifying the microorganism in the sample using said spectroscopic measurements.

The present disclosure relates to a method of identifying components present in a lipoprotein. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subpopulations that exist within lipoprotein classes are determined by correlating m/z and mass.

The invention provides methods, reagents and systems for incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to enrich the proteins or fragments thereof in a number of uses, such as proteomic analysis, imaging of diseased tissues/cells, etc.

A method of mass spectrometry is disclosed for determining if a mutated variant of a target protein is present in a sample. The method comprises subjecting the sample to fragmentation so as to cause said target protein to fragment to form second generation fragment ions, and then mass analysing these fragment ions to obtain spectral data. The method determines if a mutated variant is present in the sample by determining that an ion in the spectral data has a mass to charge ratio that differs from the mass to charge ratio of an ion that would be observed if said target protein was a normal unmutated version of said target protein, and by an amount that corresponds to a mass difference that would be caused by the target protein being a mutated variant of said target protein. This method of analysing second generation fragment ions if a rapid and efficiency method of analysing a sample.

The present invention relates to methods and other technologies that may be used to determine whether compositions (e.g., pharmaceutical compositions) comprising interleukin-10 molecules (e.g., pegylated interleukin-10) meet particular product-related specifications prior to being administered to a subject for the treatment and/or prevention of the diseases, disorders and conditions, and/or the symptoms thereof, described herein.

Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins.

Methods for identification and quantification of bile acids are disclosed. Bile acids in plasma, serum and/or blood such as a dried blood spot are used to identify subjects with a Niemann-Pick disease. The methods include measuring levels of a bile acid, such as 3β,5α,6β-trihydroxycholanic acid, N-(3β,5α,6β-trihydroxy-cholan-24-oyl)glycine, N-(3β,5α,6β-trihydroxy-cholan-24-oyl)taurine, or a combination thereof. Detection of bile acids involve mass spectroscopy and/or a combination of mass spectroscopy and liquid chromatography such as a LC-MS/MS assay. The methods can be used with sphingomyelinase assays to detect, diagnose and differentiate between Niemann-Pick A/B and Niemann-Pick C (NPC) disease.

The invention pertains to an in vitro method for detecting avian intestinal dysbiosis, the method comprising determining the presence and/or level of isoleucyl-arginine (C.sub.12H.sub.25O.sub.3N.sub.5) or isomers thereof in avian sample material wherein the presence and/or an increased level of isoleucyl-arginine (C.sub.12H.sub.25O.sub.3N.sub.5) or isomers thereof in comparison to a non-affected control is indicative for avian intestinal dysbiosis.

Provided herein are methods for generating a mass spectrometry (MS) profile of a sample from a cell composition, such as an engineered cell composition. In some embodiments, the mass spectrometry profile includes data based on one or more mass spectrometry analyses or techniques. Also provided herein are methods for, based on mass spectrometry profiles of one or more samples of such cell compositions: identifying a mass spectrometry (MS) profile of a genetically engineered cell composition comprising immune cells comprising a recombinant receptor by comparison to a reference mass spectrometry profile; characterizing a process for producing genetically engineered cell composition; assessing cell surface proteins of an engineered cell composition; and assessing a process for producing a genetically engineered cell composition.

A method for determining in a sample, by mass spectrometry, the amount of one or more analytes is described. The method comprises introducing a sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more analytes; measuring, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample. Also described is a kit comprising one or more isotopically labeled analogues as internal standards for each of the one or more analytes.